13
ANNUAL INJECTIONS
ONE 30-mg INJECTION EVERY 4 WEEKS1
For hypereosinophilic syndrome (HES), the recommended dosage of FASENRA is 30 mg (one injection) administered once every 4 weeks by subcutaneous injection.1
Annual injections: HES dosing
Mepolizumab*
39
ANNUAL INJECTIONS
THREE 100-mg INJECTIONS EVERY 4 WEEKS2
FASENRA is a single monthly subcutaneous injection of 30 mg for the treatment of HES1
AT-HOME ADMINISTRATION
Available in a single-dose autoinjector FASENRA Pen
Patients/caregivers may administer with FASENRA Pen after proper training in subcutaneous injection technique and after the healthcare professional determines it is appropriate.1
IN-OFFICE ADMINISTRATION
Available in single-dose prefilled syringes
FASENRA is indicated for use under the guidance of a healthcare professional. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended.1
See full Prescribing Information for complete dosing and administration information and Instructions for Use.
HES DOSING FAQs
For the treatment of adult and adolescent patients aged 12 years and older with hypereosinophilic syndrome (HES), the recommended dosage of FASENRA is 30 mg (one injection) administered once every 4 weeks by subcutaneous injection.1
Reference: 1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
FASENRA is for subcutaneous use only. FASENRA is intended for use under the guidance of a healthcare provider. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended. The recommended dosage of FASENRA for HES is 30 mg (one injection) administered once every 4 weeks by subcutaneous injection. FASENRA is available for in-office or at-home administration. In-office treatment is administered by a healthcare professional via a prefilled syringe while the FASENRA Pen autoinjector is used at home by the patient or caregiver, following proper training.1
Reference: 1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
Yes, the autoinjector FASENRA Pen is intended for administration by patients/caregivers. Patients/caregivers may inject after proper training in subcutaneous injection technique, and after the healthcare provider determines it is appropriate. FASENRA is also available in a prefilled syringe for administration by a healthcare provider.1
FASENRA is intended for use under the guidance of a healthcare provider. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended.1
Reference: 1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
*Mepolizumab is indicated for the treatment of adult and pediatric patients aged 12 years and older with HES for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. For HES, the recommended dose of mepolizumab is 300 mg as 3 separate 100-mg injections administered subcutaneously once every 4 weeks.2
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Known hypersensitivity to benralizumab or excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria, rash) have occurred after administration of FASENRA. These reactions generally occur within hours of administration, but in some instances have a delayed onset (ie, days). Discontinue in the event of a hypersensitivity reaction.
Acute Asthma Symptoms or Deteriorating Disease
FASENRA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.
Reduction of Corticosteroid Dosage
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.
Parasitic (Helminth) Infection
It is unknown if FASENRA will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with FASENRA. If patients become infected while receiving FASENRA and do not respond to anti-helminth treatment, discontinue FASENRA until infection resolves.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥ 5%):
- Asthma: headache, pharyngitis
- EGPA: headache
- HES: headache, hypersensitivity reactions, influenza-like illness
Injection site reactions (eg, pain, erythema, pruritus, papule) occurred at a rate of 2.2% in patients treated with FASENRA compared with 1.9% in patients treated with placebo in asthma exacerbation studies.
USE IN SPECIFIC POPULATIONS
The data on pregnancy exposure from the clinical trials are insufficient to inform on drug-associated risk. Monoclonal antibodies such as benralizumab are transported across the placenta during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.
INDICATIONS
FASENRA is indicated for:
- the add-on maintenance treatment of patients with severe asthma aged 6 years and older and with an eosinophilic phenotype. FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus
- the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)
- the treatment of adult and adolescent patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause
Please read full Prescribing Information, including Patient Information.
You may report side effects related to AstraZeneca products 
.
References
Reference
1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
2. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8 3. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Supplementary information published online March 31, 2026. doi:10.1038/s41591-026-04315-8
1. Khoury P, Akuthota P, Kwon N, Steinfeld J, Roufosse F. HES and EGPA: two sides of the same coin. Mayo Clin Proc. 2023;98(7):1054-1070. 2. Valent P, Klion AD, Roufosse F, et al. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy. 2023;78(1):47-59. 3. Silver J, Kovalszki A, Strobel MJ, et al. Burden of hypereosinophilic syndromes in the United States: patients' perspective. J Allergy Clin Immunol Glob. 2025;4(3):100501. 4. Dolin P, Pongdee T, Jain P, et al. Disease burden of idiopathic and lymphocytic hypereosinophilic syndrome in the United States: evidence from a real-world retrospective study of de-identified electronic health records and insurance claims. Poster presented at: The American Society of Hematology Annual Meeting; December 7–10, 2024; San Diego, CA. Poster 2316.
1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
2. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8 3. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Supplementary information published online March 31, 2026. doi:10.1038/s41591-026-04315-8
1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
2. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8
1. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8 2. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026. 3. Data on File, US-107579, AZPLP.
1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
2. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8 3. Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Supplementary information published online March 31, 2026. doi:10.1038/s41591-026-04315-8
1. FASENRA® (benralizumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
2. Nucala® (mepolizumab) [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; August 2025.
